**Study Protocol Assessment Form**

|  |  |
| --- | --- |
| **STUDY PROTOCOL INFORMATION** | |
| **FEU-NRMF IERC Code:[[1]](#footnote-1)** |  |
| **Study Protocol Title:** |  |
| **Principal Investigator:** | <Title, Name, Surname> |
| **Study Protocol Submission Date:** | mm/dd/yyyy> (to be filled by the IERC staff) |

**INSTRUCTIONS**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| To the Principal Investigator: | Please indicate in the space provided below whether or not the specified assessment point is addressed by your study protocol. To facilitate the evaluation of the assessment point, indicate the page and paragraph where this information can be found. | | | | |
| To the Primary Reviewer: | Please evaluate how the assessment points outlined below have been appropriately addressed by the study protocol, as applicable, by confirming the submitted information and putting your comments in the space provided under “REVIEWER COMMENTS.” Finalize your review by indicating your conclusions under “RECOMMENDED ACTION” and signing in space provided for the primary reviewer. | | | | |
|  | **To be filled out by the PI** | | | |  |
| **ASSESSMENT POINTS** | Indicate if the study protocol contains the specified assessment point | | | Page and paragraph where it is found | **REVIEWER COMMENTS** |
| 1. **SCIENTIFIC DESIGN** | **YES** | | **N/A** |  |  |
| * 1. **Objectives**   *Review of viability of expected output* |  | |  |  |  |
| * 1. **Literature review**   *Review of results of previous animal/human studies showing known risks and benefits of intervention, including known adverse drug effects, in case of drug trials* |  | |  |  |  |
| * 1. **Research design**   *Review of appropriateness of design in view of objectives* |  | |  |  |  |
| * 1. **Sampling design**   *Review of appropriateness of sampling methods and techniques* |  | |  |  |  |
| * 1. **Study Procedure**   *Review of appropriateness and feasibility of data collection method* |  | |  |  |  |
| * 1. **Operational Definition of Variables**   *Review of operational definition of dependent, independent, and confounding variables* |  | |  |  |  |
| * 1. **Sample size**   *Review of computation of sample size* |  | |  |  |  |
| * 1. **Data analysis plan**   *Review of appropriateness of statistical and non-statistical methods of data analysis* |  | |  |  |  |
| * 1. **Inclusion criteria**   *Review of precision of criteria both for scientific merit and safety concerns; and of equitable selection* |  | |  |  |  |
| * 1. **Exclusion criteria**   *Review of criteria precision both for scientific merit and safety concerns; and of justified exclusion* |  | |  |  |  |
| * 1. **Withdrawal criteria**   *Review of criteria precision both for scientific merit and safety concerns* |  | |  |  |  |
| 1. **CONDUCT OF STUDY** |  | |  |  |  |
| * 1. **Specimen handling**   *Review of specimen storage, access, disposal, and terms of use* |  | |  |  |  |
| * 1. **PI qualifications**   *Review of CV and relevant certifications (including Conflict of Interest declaration) to ascertain capability to manage study related risks* |  | |  |  |  |
| * 1. **Suitability of site**   *Review of adequacy of qualified staff and infrastructures, including applicability of* ***FEU-NRMF IERC FORM2(E) 2022 and FEU-NRMF IERC FORM2(F) 2022*** |  | |  |  |  |
| * 1. **Duration**   *Review of length/extent of human participant involvement in the study* |  | |  |  |  |
| 1. **ETHICAL CONSIDERATIONS** |  | |  |  |  |
| * 1. **Conflict of interest**   *Review of management of conflict arising from financial, familial, or proprietary considerations of the PI, sponsor, or the study site* |  | |  |  |  |
| * 1. **Privacy and confidentiality**   *Review of measures or guarantees to protect privacy and confidentiality of participant information as indicated by data collection methods including data protection plans* |  | |  |  |  |
| * 1. **Informed consent process**   *Review of application of the principle of respect for persons,**who may solicit consent, how and when it will be done; who may give consent especially in case of special populations like minors and those who are not legally competent to give consent, or indigenous people which require additional clearances* |  | |  |  |  |
| * 1. **Vulnerability**   *Review of involvement of vulnerable study populations and impact on informed consent (see 3.3). Vulnerable groups include children, the elderly, ethnic and racial minority groups, the homeless, prisoners, people with incurable disease, people who are politically powerless, or junior members of a hierarchical group* |  | |  |  |  |
| * 1. **Recruitment**   *Review of manner of recruitment including appropriateness of identified recruiting parties* |  | |  |  |  |
| * 1. **Assent**   *Review of feasibility of obtaining assent vis à vis incompetence to consent; Review of applicability of the assent age brackets in children:*  *0-under 7: No assent required; Parent/Guardian Consent/Permission Form required*  *7 – under 12: Verbal Assent Form and Parent/Guardian Consent/Permission Form required*  *12 – under 15: Simplified Assent Form and Parent/Guardian Consent/Permission Form required*  *15 – under 18: Co-sign Informed Consent Form with parents* |  | |  |  |  |
| * 1. **Risks**   *Review of level of risk and measures to mitigate these risks (including physical, psychological, social, economic), including plans for adverse event management; Review of justification for allowable use of placebo as detailed in the Declaration of Helsinki (as applicable). State risk assessment as follows:*  ***Minimal –*** *the probability and magnitude of harm or discomfort anticipated in the research are not greater than those ordinarily encountered in daily life or during routine physical and psychological examinations or tests (ex. ECG, DEXA Scan, anthropometrics)*  ***Low –*** *involves minor increase over minimal risk; risks commensurate with those inherent in actual or expected physiological, psychological, social or educational situations; healthy volunteers performing low-risk research procedures (ex. IV infusion or euglycemic clamp); minimal risk studies that involve special populations (ex. mentally handicapped); studies that involve sensitive information; post-marketing studies (phase IV drug/device studies as defined by FDA)*  ***Moderate*** *– risks are greater than low risk, but their surveillance and protection are adequate to identify adverse events promptly and keep their effects minimal (i.e. risks can be controlled); reasonable risks in relation to anticipated benefits to research participants and the importance of the knowledge that may reasonably be expected to result from the study; benefits are greater than the risks*  ***High –*** *involves greater-than-low risk without prospect of direct benefit to research participants, but the study is likely to yield generalizable knowledge about the disorder or condition studied; in situations where the prospect of direct benefit to study participant exists, the risks associated with study procedures are considered substantial* |  | |  |  |  |
| * 1. **Benefits**   *Review of potential direct benefit to participants; the potential to yield generalizable knowledge about the participants’ condition/problem; non-material compensation to participant (health education or other creative benefits), where no clear, direct benefit from the project will be received by the participant* |  | |  |  |  |
| * 1. **Incentives or compensation**   *Review of amount and method of compensations, financial incentives, or reimbursement of study-related expenses* |  | |  |  |  |
| * 1. **Community considerations**   *Review of impact of the research on the community where the research occurs and/or to whom findings can be linked; including issues like stigma or draining of local capacity; sensitivity to cultural traditions, and involvement of the community in decisions about the conduct of study* |  | |  |  |  |
| * 1. **Collaborative study terms of reference**   *Review of terms of collaborative study especially in case of multi-country/multi-institutional studies, including intellectual property rights, publication rights, information and responsibility sharing, transparency, and capacity building* |  | |  |  |  |
| **RECOMMENDED ACTION:** | | | | | |
| * APPROVAL | | | | | |
| * MINOR MODIFICATIONS | | | | | |
| * MAJOR MODIFICATIONS | | | | | |
| * DISAPPROVAL | |  | | | |
| **SPECIFIC RECOMMENDATIONS:** | | | | | |

|  |  |  |  |
| --- | --- | --- | --- |
| **PRIMARY REVIEWER** |  | Signature |  |
| Date: <mm/dd/yyyy> |  | Name | <Title, Name, Surname> |
| **IERC SECRETARY** |  | Signature |  |
| Date: <mm/dd/yyyy> |  | Name | <Title, Name, Surname> |
| **IERC CHAIR** |  | Signature |  |
| Date: <mm/dd/yyyy> |  | Name | <Title, Name, Surname> |

1. To be issued upon initial processing by FEU-NRMF IERC [↑](#footnote-ref-1)